BACKGROUND: Previous work has identified CD11c(+)CD1c(-) dendritic cells (DCs) as the major "inflammatory" dermal DC population in patients with psoriasis vulgaris and CD1c(+) DCs as the "resident" cutaneous DC population. OBJECTIVE: We sought to further define molecular differences between these 2 myeloid dermal DC populations. METHODS: Inflammatory and resident DCs were single-cell sorted from lesional skin biopsy specimens of patients with psoriasis, and the transcriptome of CD11c(+)CD1c(-) versus CD1c(+) DCs was determined. Results were confirmed with RT-PCR, flow cytometry, immunohistochemistry, and double-labeled immunofluorescence. Human keratinocytes were cultured for functional studies. RESULTS: TNF-related apoptosis-inducing ligand (TRAIL), Toll-like receptors 1 and 2, S100A12/ENRAGE, CD32, and many other inflammatory products were differentially expressed in inflammatory DCs compared with resident DCs. Flow cytometry and immunofluorescence confirmed higher protein expression on CD1c(-) versus CD1c(+) DCs. TRAIL receptors, death receptor 4, and decoy receptor 2 were expressed in keratinocytes and dermal cells. In vitro culture of keratinocytes with TRAIL induced CCL20 chemokine. CONCLUSIONS: CD11c(+)CD1c(-) inflammatory DCs in psoriatic lesional skin express a wide range of inflammatory molecules compared with skin-resident CD1c(+) DCs. Some molecules made by inflammatory DCs, including TRAIL, could have direct effects on keratinocytes or other skin cell types to promote disease pathogenesis. Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
BACKGROUND: Previous work has identified CD11c(+)CD1c(-) dendritic cells (DCs) as the major "inflammatory" dermal DC population in patients with psoriasis vulgaris and CD1c(+) DCs as the "resident" cutaneous DC population. OBJECTIVE: We sought to further define molecular differences between these 2 myeloid dermal DC populations. METHODS: Inflammatory and resident DCs were single-cell sorted from lesional skin biopsy specimens of patients with psoriasis, and the transcriptome of CD11c(+)CD1c(-) versus CD1c(+) DCs was determined. Results were confirmed with RT-PCR, flow cytometry, immunohistochemistry, and double-labeled immunofluorescence. Human keratinocytes were cultured for functional studies. RESULTS:TNF-related apoptosis-inducing ligand (TRAIL), Toll-like receptors 1 and 2, S100A12/ENRAGE, CD32, and many other inflammatory products were differentially expressed in inflammatory DCs compared with resident DCs. Flow cytometry and immunofluorescence confirmed higher protein expression on CD1c(-) versus CD1c(+) DCs. TRAIL receptors, death receptor 4, and decoy receptor 2 were expressed in keratinocytes and dermal cells. In vitro culture of keratinocytes with TRAIL induced CCL20 chemokine. CONCLUSIONS:CD11c(+)CD1c(-) inflammatory DCs in psoriatic lesional skin express a wide range of inflammatory molecules compared with skin-resident CD1c(+) DCs. Some molecules made by inflammatory DCs, including TRAIL, could have direct effects on keratinocytes or other skin cell types to promote disease pathogenesis. Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
Authors: Asifa S Haider; Michelle A Lowes; Mayte Suárez-Fariñas; Lisa C Zaba; Irma Cardinale; Artemis Khatcherian; Inna Novitskaya; Knut M Wittkowski; James G Krueger Journal: J Immunol Date: 2008-02-01 Impact factor: 5.422
Authors: Michelle A Lowes; Toyoko Kikuchi; Judilyn Fuentes-Duculan; Irma Cardinale; Lisa C Zaba; Asifa S Haider; Edward P Bowman; James G Krueger Journal: J Invest Dermatol Date: 2008-01-17 Impact factor: 8.551
Authors: Lisa C Zaba; Mayte Suárez-Fariñas; Judilyn Fuentes-Duculan; Kristine E Nograles; Emma Guttman-Yassky; Irma Cardinale; Michelle A Lowes; James G Krueger Journal: J Allergy Clin Immunol Date: 2009-11 Impact factor: 10.793
Authors: Mary M Kavurma; Michael Schoppet; Yuri V Bobryshev; Levon M Khachigian; Martin R Bennett Journal: J Biol Chem Date: 2008-01-03 Impact factor: 5.157
Authors: Lisa C Zaba; Judilyn Fuentes-Duculan; Ralph M Steinman; James G Krueger; Michelle A Lowes Journal: J Clin Invest Date: 2007-09 Impact factor: 14.808
Authors: Markus Weckmann; Adam Collison; Jodie L Simpson; Matthias V Kopp; Peter A B Wark; Mark J Smyth; Hideo Yagita; Klaus I Matthaei; Nicole Hansbro; Bruce Whitehead; Peter G Gibson; Paul S Foster; Joerg Mattes Journal: Nat Med Date: 2007-10-14 Impact factor: 53.440
Authors: Lisa C Zaba; Irma Cardinale; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; Mayte Suárez Fariñas; Judilyn Fuentes-Duculan; Inna Novitskaya; Artemis Khatcherian; Mark J Bluth; Michelle A Lowes; James G Krueger Journal: J Exp Med Date: 2007-11-26 Impact factor: 14.307
Authors: Michelle A Lowes; Chris B Russell; David A Martin; Jennifer E Towne; James G Krueger Journal: Trends Immunol Date: 2013-01-03 Impact factor: 16.687
Authors: Benjamin H Kaffenberger; Grace L Lee; Kelly Tyler; Derek V Chan; Wael Jarjour; Maria E Ariza; Marshall V Williams; Henry K Wong Journal: Hum Vaccin Immunother Date: 2014-02-03 Impact factor: 3.452